Atnahs Pharma shops €354 million term B at Euribor plus 475-500 bps

By Sara Rosenberg

New York, Sept. 11 – Atnahs Pharma (Antigua Bidco Ltd.) is talking its €354 million seven-year covenant-lite term loan B (B2//B+) at Euribor plus 475 basis points to 500 bps with a 0% floor and an original issue discount of 99, according to a market source.

Barclays is the lead bank on the deal.

Commitments are due on Sept. 25, the source said.

Atnahs is a U.K.-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.